Tecnoglass Inc. reported record second quarter 2025 results, with total revenues increasing 16.3% year-over-year to $255.5 million. This growth was driven by double-digit organic expansion in both single-family residential revenues, up 14.5% to $109.6 million, and multi-family/commercial revenues, which grew 17.8%.
The company achieved a gross margin of 44.7%, an expansion of 400 basis points year-over-year, reflecting benefits from stronger pricing and operating leverage. Adjusted EBITDA increased 24.5% year-over-year to $79.8 million, representing 31.2% of total revenues. Net income was $44.1 million, or $0.94 per diluted share, with adjusted net income at $48.5 million, or $1.03 per diluted share.
Tecnoglass's backlog expanded 17.2% year-over-year to a record $1.2 billion, providing revenue visibility well into 2026. The company also signed a lease for a new West Coast showroom to promote its 'Legacy' aluminum product line, supporting ongoing geographical expansion.
The feasibility study to build a new fully automated, state-of-the-art manufacturing facility in Florida is continuing, with the company narrowing its search to two potential locations. This plant is expected to address future growth needs beyond current installed capacity and yield advantages in lead-times, transportation costs, and supply chain efficiencies.
Tecnoglass strengthened its full year 2025 financial guidance, now expecting revenues in the range of $980 million to $1.02 billion, reflecting approximately 12% growth at the midpoint. Adjusted EBITDA guidance was narrowed to $310 million to $325 million, representing approximately 15% growth at the midpoint, with pricing initiatives and mitigation efforts expected to offset a projected $25 million full-year impact from elevated input costs and tariffs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.